Dataset Viewer
instruction
stringlengths 99
248
| response
stringlengths 178
304
| text
stringlengths 310
585
|
|---|---|---|
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for ISS Disease Stage is I or II patients | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for ISS Disease Stage is I or II patients
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with I or II ISS Disease Stage | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with I or II ISS Disease Stage
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) |
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for I or II ISS Disease Stage patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) | ### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for I or II ISS Disease Stage patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) |
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for I or II ISS Disease Stage patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) | ### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for I or II ISS Disease Stage patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) |
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at I or II ISS Disease Stage? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) | ### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at I or II ISS Disease Stage?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) |
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for I or II ISS Disease Stage patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) | ### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for I or II ISS Disease Stage patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) |
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for I or II ISS Disease Stage patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) | ### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for I or II ISS Disease Stage patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) |
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for I or II ISS Disease Stage patients. Can you help? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) | ### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for I or II ISS Disease Stage patients. Can you help?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) |
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the I or II ISS Disease Stage group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) | ### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the I or II ISS Disease Stage group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) |
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the I or II ISS Disease Stage group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) | ### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the I or II ISS Disease Stage group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) |
What is the PFS hazard ratio and 95% CI for I or II ISS Disease Stage patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) | ### Instruction: What is the PFS hazard ratio and 95% CI for I or II ISS Disease Stage patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for ISS Disease Stage is III patients | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for ISS Disease Stage is III patients
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with III ISS Disease Stage | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with III ISS Disease Stage
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) |
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for III ISS Disease Stage patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) | ### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for III ISS Disease Stage patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) |
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for III ISS Disease Stage patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) | ### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for III ISS Disease Stage patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) |
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at III ISS Disease Stage? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) | ### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at III ISS Disease Stage?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) |
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for III ISS Disease Stage patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) | ### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for III ISS Disease Stage patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) |
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for III ISS Disease Stage patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) | ### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for III ISS Disease Stage patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) |
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for III ISS Disease Stage patients. Can you help? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) | ### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for III ISS Disease Stage patients. Can you help?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) |
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the III ISS Disease Stage group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) | ### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the III ISS Disease Stage group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) |
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the III ISS Disease Stage group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) | ### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the III ISS Disease Stage group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) |
What is the PFS hazard ratio and 95% CI for III ISS Disease Stage patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) | ### Instruction: What is the PFS hazard ratio and 95% CI for III ISS Disease Stage patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Age is <= 65 patients | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Age is <= 65 patients
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with <= 65 Age | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with <= 65 Age
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) |
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for <= 65 Age patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) | ### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for <= 65 Age patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) |
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for <= 65 Age patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) | ### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for <= 65 Age patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) |
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at <= 65 Age? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) | ### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at <= 65 Age?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) |
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for <= 65 Age patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) | ### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for <= 65 Age patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) |
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for <= 65 Age patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) | ### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for <= 65 Age patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) |
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for <= 65 Age patients. Can you help? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) | ### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for <= 65 Age patients. Can you help?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) |
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the <= 65 Age group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) | ### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the <= 65 Age group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) |
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the <= 65 Age group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) | ### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the <= 65 Age group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) |
What is the PFS hazard ratio and 95% CI for <= 65 Age patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) | ### Instruction: What is the PFS hazard ratio and 95% CI for <= 65 Age patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Age is > 65 patients | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Age is > 65 patients
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with > 65 Age | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with > 65 Age
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) |
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for > 65 Age patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) | ### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for > 65 Age patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) |
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for > 65 Age patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) | ### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for > 65 Age patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) |
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at > 65 Age? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) | ### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at > 65 Age?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) |
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for > 65 Age patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) | ### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for > 65 Age patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) |
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for > 65 Age patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) | ### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for > 65 Age patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) |
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for > 65 Age patients. Can you help? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) | ### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for > 65 Age patients. Can you help?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) |
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the > 65 Age group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) | ### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the > 65 Age group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) |
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the > 65 Age group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) | ### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the > 65 Age group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) |
What is the PFS hazard ratio and 95% CI for > 65 Age patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) | ### Instruction: What is the PFS hazard ratio and 95% CI for > 65 Age patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Region is North America patients | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Region is North America patients
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with North America Region | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with North America Region
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) |
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for North America Region patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) | ### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for North America Region patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) |
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for North America Region patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) | ### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for North America Region patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) |
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at North America Region? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) | ### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at North America Region?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) |
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for North America Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) | ### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for North America Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) |
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for North America Region patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) | ### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for North America Region patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) |
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for North America Region patients. Can you help? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) | ### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for North America Region patients. Can you help?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) |
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the North America Region group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) | ### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the North America Region group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) |
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the North America Region group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) | ### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the North America Region group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) |
What is the PFS hazard ratio and 95% CI for North America Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) | ### Instruction: What is the PFS hazard ratio and 95% CI for North America Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Region is Europe patients | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Region is Europe patients
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with Europe Region | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with Europe Region
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) |
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for Europe Region patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) | ### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for Europe Region patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) |
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Europe Region patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) | ### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Europe Region patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) |
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at Europe Region? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) | ### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at Europe Region?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) |
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for Europe Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) | ### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for Europe Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) |
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Europe Region patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) | ### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Europe Region patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) |
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Europe Region patients. Can you help? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) | ### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Europe Region patients. Can you help?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) |
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the Europe Region group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) | ### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the Europe Region group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) |
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the Europe Region group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) | ### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the Europe Region group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) |
What is the PFS hazard ratio and 95% CI for Europe Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) | ### Instruction: What is the PFS hazard ratio and 95% CI for Europe Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Region is Asia - Pacific patients | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Region is Asia - Pacific patients
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with Asia - Pacific Region | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with Asia - Pacific Region
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) |
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for Asia - Pacific Region patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) | ### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for Asia - Pacific Region patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) |
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Asia - Pacific Region patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) | ### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Asia - Pacific Region patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) |
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at Asia - Pacific Region? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) | ### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at Asia - Pacific Region?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) |
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for Asia - Pacific Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) | ### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for Asia - Pacific Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) |
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Asia - Pacific Region patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) | ### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Asia - Pacific Region patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) |
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Asia - Pacific Region patients. Can you help? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) | ### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Asia - Pacific Region patients. Can you help?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) |
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the Asia - Pacific Region group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) | ### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the Asia - Pacific Region group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) |
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the Asia - Pacific Region group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) | ### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the Asia - Pacific Region group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) |
What is the PFS hazard ratio and 95% CI for Asia - Pacific Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) | ### Instruction: What is the PFS hazard ratio and 95% CI for Asia - Pacific Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Baseline ECOG Score is 0-1 patients | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Baseline ECOG Score is 0-1 patients
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with 0-1 Baseline ECOG Score | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with 0-1 Baseline ECOG Score
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) |
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for 0-1 Baseline ECOG Score patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) | ### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for 0-1 Baseline ECOG Score patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) |
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 0-1 Baseline ECOG Score patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) | ### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 0-1 Baseline ECOG Score patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) |
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at 0-1 Baseline ECOG Score? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) | ### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at 0-1 Baseline ECOG Score?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) |
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for 0-1 Baseline ECOG Score patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) | ### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for 0-1 Baseline ECOG Score patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) |
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 0-1 Baseline ECOG Score patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) | ### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 0-1 Baseline ECOG Score patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) |
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 0-1 Baseline ECOG Score patients. Can you help? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) | ### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 0-1 Baseline ECOG Score patients. Can you help?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) |
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the 0-1 Baseline ECOG Score group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) | ### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the 0-1 Baseline ECOG Score group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) |
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the 0-1 Baseline ECOG Score group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) | ### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the 0-1 Baseline ECOG Score group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) |
What is the PFS hazard ratio and 95% CI for 0-1 Baseline ECOG Score patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) | ### Instruction: What is the PFS hazard ratio and 95% CI for 0-1 Baseline ECOG Score patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Baseline ECOG Score is 2 patients | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Baseline ECOG Score is 2 patients
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with 2 Baseline ECOG Score | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with 2 Baseline ECOG Score
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) |
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for 2 Baseline ECOG Score patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) | ### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for 2 Baseline ECOG Score patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) |
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 2 Baseline ECOG Score patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) | ### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 2 Baseline ECOG Score patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) |
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at 2 Baseline ECOG Score? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) | ### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at 2 Baseline ECOG Score?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) |
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for 2 Baseline ECOG Score patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) | ### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for 2 Baseline ECOG Score patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) |
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 2 Baseline ECOG Score patients? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) | ### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 2 Baseline ECOG Score patients?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) |
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 2 Baseline ECOG Score patients. Can you help? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) | ### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 2 Baseline ECOG Score patients. Can you help?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) |
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the 2 Baseline ECOG Score group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) | ### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the 2 Baseline ECOG Score group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) |
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the 2 Baseline ECOG Score group? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) | ### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the 2 Baseline ECOG Score group?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) |
What is the PFS hazard ratio and 95% CI for 2 Baseline ECOG Score patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) | ### Instruction: What is the PFS hazard ratio and 95% CI for 2 Baseline ECOG Score patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34) |
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Baseline Creatinine Clearance (ML / Min) is >=15 To < 50 patients | In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline Creatinine Clearance (ML / Min) is >=15 To < 50 was 0.41 with a 95% confidence interval (CI) of (0.19, 0.90) | ### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Baseline Creatinine Clearance (ML / Min) is >=15 To < 50 patients
### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline Creatinine Clearance (ML / Min) is >=15 To < 50 was 0.41 with a 95% confidence interval (CI) of (0.19, 0.90) |
End of preview. Expand
in Data Studio
- Downloads last month
- 37